Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.
Mansi AroraJames M BogenbergerAmro AbdelrahmanJennifer L LeitingXianfeng ChenJan B EganAradhana KasimsettyElzbieta LenkiewiczSmriti MalasiPedro Luiz Serrano UsonBolni Marius NagaloYumei ZhouMarcela A SalomaoHeidi E KosiorekEsteban BraggioMichael T BarrettMark J TrutyMitesh J BoradPublished in: Cancer chemotherapy and pharmacology (2020)
NUC1031 did not exhibit evidence of superior activity over gemcitabine, as a single-agent, or in combination with cisplatin, in either our in vivo or in vitro BTC models. Given that the largest Phase 3 study (ClinicalTrials.gov: NCT0314666) to date in BTC is underway (N = 828) comparing NUC1031/cisplatin to gemcitabine/cisplatin, our results suggest that a more conservative clinical evaluation path would be more appropriate.